Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Zepatier (elbasvir and grazoprevir by Year
Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%)
Merck Zepatier (elbasvir and grazoprevir: -99.0% in FY2018, down 157.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2018 figure comes from
“|| Zepatier | 455 | 1,660 | -73 | 8 | 771 | -99 | 447 | 888 | -50”
Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | -99.0% | -157.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 58.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Zepatier (elbasvir and grazoprevir (%), annual FY2017–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zepatier-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.